Warfarin replacements: Mechanisms underlying emerging agents

Canadian Journal of Cardiology

Volumn 24, Issue SUPPL.C, 2008, Pages 56C-60C

  Turpie, Alexander G G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Anticoagulation; Apixaban; Dabigatran; Factor xa; Rivaroxaban; Warfarin

Indexed keywords

EID: 61849184049     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)71040-7     Document Type: Conference Paper

References (27)

1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-33S.
2. Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: The international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007;2:83-91.
3. Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005;165:1458-64.
4. Turpie AG. Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-47.
5. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:263-5
6. Eriksson BI, Dahl OE, van Dijk CN, et al. A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (the RE-MODEL trial). Blood 2006;108:(Abst) 573.
7. Friedman RJ, Caprini JA, Comp PC, et al. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. J Thromb Haemost 2007;5:(Abst) O-W-051.
8. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate is effective and safe for the extended prophylaxis of venous thromboembolism following total hip replacement. J Thromb Haemost 2007;5:O-W-049. (Abst)
9. Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopaedic surgery. J Thromb Haemost 2007;5:O-W-050. (Abst)
10. Wallentin LC, Ezekowitz M, Simmers TA, et al. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation - a dose finding trial with comparison to warfarin. Eur Heart J 2005;26(Suppl 1):P2949. (Abst)
11. The Petro-Ex Investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. Cerebrovasc Dis 2006;21:5. (Abst)
12. Luettgen JM, Bozarth TA, Bozarth JM, et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable Factor Xa inhibitor. Blood 2006;108:4130. (Abst)
13. He K, He B, Grace JE, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor. Blood 2006;108:910. (Abst)
14. Lassen MR, Davidson BL, Gallus A, et al. A phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of apixaban, a new oral Factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery on behalf of the apixaban investigators. Blood 2006;108:574. (Abst)
15. Buller HR. A dose finding study of the oral direct Factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli investigators. J Thromb Haemost 2007;5:(Abst) O-S-003.
16. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-21.
17. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21.
18. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80.
19. Kubitza D, Becka M, Mueck W, et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. Blood 2006;108:(Abst) 905.
20. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-8.
21. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3:2479-86.
22. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-81.
23. Eriksson BI, Borris LC, Friedman RJ, et al RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
24. Kakkar AK, Brenner B, Dahl OE, et al for the RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
25. Lassen MR, Ageno W, Borris LC, et al RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
26. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116:180-7.
27. Buller HR. Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dosefinding study. Eur Heart J 2006;27:761. (Abst)